Following its success in early detection of cerebral ischemia, diffusion-weighted imaging (DWI) has been increasingly used in cancer diagnosis and treatment evaluation. These applications are propelled by the rapid development of novel diffusion models to extract biologically valuable information from diffusion-weighted MR signals, and significant advances in MR hardware that has enabled image acquisition with high b-values. This article reviews recent technical developments and clinical applications in cancer imaging using DWI, with a special emphasis on high b-value diffusion models. The article is organized in four sections. First, we provide an overview of diffusion models that are relevant to cancer imaging. The model parameters are discussed in relation to three tissue properties-cellularity, vascularity, and microstructures. An emphasis is placed on characterization of microstructural heterogeneity, given its novelty and close relevance to cancer. Second, we illustrate diffusion MR clinical applications in each of the following three categories: 1) cancer detection and diagnosis; 2) cancer grading, staging, and classification; and 3) cancer treatment response prediction and evaluation. Third, we discuss several practical issues, including selection of image acquisition parameters, reproducibility and reliability, motion management, image distortion, etc., that are commonly encountered when applying DWI to cancer in clinical settings. Lastly, we highlight a few ongoing challenges and provide some possible future directions, particularly in the area of establishing standards via well-organized multicenter clinical trials to accelerate clinical translation of advanced DWI techniques to improving cancer care on a large scale. Undoubtedly, DWI for cancer applications has benefited immensely from the rich experience gained from stroke imaging. However, applying DWI to cancer is not a simple extension of prior success with ischemic stroke. First, cancer is a disease with a much broader scope than stroke, affecting many organ systems beyond the brain. As such, new diffusion imaging strategies must be developed and a number of new challenges, such as respiratory motion and drastic magnetic susceptibility variations in the body, must be addressed. Second, compared to cerebral ischemia, cancer is a more complex disease that involves many biological processes spanning from genetics, metabolism, microenvironment, microstructures, to angiogenesis. This complexity presents new challenges for DWI to probe some of these biological processes. Third, DWI of cancer places a stronger emphasis on quantitative markers with biological significance. Hence, 14 In this review we focus on the three aforementioned aspects-cellularity, vascularity, and microstructuresthat diffusion MRI can offer for cancer detection, characterization, and therapy evaluation. A special emphasis will be placed on microstructural characterization at high b-values, given its novelty and lack of systematic review in this rapidly growing area with immense potential. This review is organized in four sections. First, we provide an overview of diffusion models that are particularly relevant to cancer imaging. The model parameters will be discussed in relation to the three tissue properties-cellularity, vascularity, and microstructures. Second, we review selected diffusion MRI clinical applications in each of the following three areas: 1) cancer detection and diagnosis; 2) cancer grading, staging, and classification; and 3) cancer treatment evaluation and prediction. We recognize that organ-specific cancer types have varying pathological characteristics and clinical context, leading to differences in the use and interpretation of DWI. As such, the review of the clinical literature will focus on illustration of general principles without delving into the specific cancer types. In addition, preclinical studies using animal models will not be covered in our review. Third, we will discuss several practical issues, including selection of image acquisition parameters, reproducibility and reliability, motion management, image distortion, etc., that are commonly encountered when applying DWI to cancer in clinical settings. Lastly, we highlight a few ongoing challenges and provide some possible future directions.
developing various diffusion models and understanding the associated model parameters become critical. Lastly, applications of DWI to cancer are not limited to detection and diagnosis, but extend into areas such as cancer staging, grading, treatment evaluation, and even prediction.
The differences outlined above represent enormous opportunities for developing advanced DWI techniques with a focus on cancer applications. To date, DWI for the vast majority of cancer applications has been relying on the simplest diffusion model based on monoexponential signal decay that yields a single diffusion parameter-the apparent diffusion coefficient (ADC). Despite its simplicity, this monoexponential model has worked remarkably well in a broad range of cancer applications. Many studies have provided compelling evidence relating ADC to tissue cellularity, 7, 8 an important cellular measure during cancer progression and treatment-induced regression. More recently, using an established model based on intravoxel incoherent motion (IVIM), 9, 10 an increasing number of studies have suggested that measurement of the "fast diffusion" component in tissues can be related to perfusion, providing an indirect measure of tissue vascularity 11 and the associated tumor angiogenesis.
Very recently, with the development of a wealth of advanced diffusion models, diffusion MRI has been shown capable of probing tissue microstructures at a subvoxel level. 5 Although the majority of tissue microstructural studies are performed on the brain, applications to the non-central nervous system (CNS) have emerged, including but not limited to prostate cancer, 12 breast cancer, 13 and gastrointestinal stromal tumor (GIST). 14 In this review we focus on the three aforementioned aspects-cellularity, vascularity, and microstructuresthat diffusion MRI can offer for cancer detection, characterization, and therapy evaluation. A special emphasis will be placed on microstructural characterization at high b-values, given its novelty and lack of systematic review in this rapidly growing area with immense potential. This review is organized in four sections. First, we provide an overview of diffusion models that are particularly relevant to cancer imaging. The model parameters will be discussed in relation to the three tissue properties-cellularity, vascularity, and microstructures. Second, we review selected diffusion MRI clinical applications in each of the following three areas: 1) cancer detection and diagnosis; 2) cancer grading, staging, and classification; and 3) cancer treatment evaluation and prediction. We recognize that organ-specific cancer types have varying pathological characteristics and clinical context, leading to differences in the use and interpretation of DWI. As such, the review of the clinical literature will focus on illustration of general principles without delving into the specific cancer types. In addition, preclinical studies using animal models will not be covered in our review. Third, we will discuss several practical issues, including selection of image acquisition parameters, reproducibility and reliability, motion management, image distortion, etc., that are commonly encountered when applying DWI to cancer in clinical settings. Lastly, we highlight a few ongoing challenges and provide some possible future directions.
Diffusion Models and Their Biophysical Bases
Diffusion-Weighted MR Signals It is well known that the MRI signal can be attenuated by diffusion. For water diffusion in a homogeneous medium where the diffusion displacement follows a Gaussian distribution (eg, in the cerebrospinal fluid), a simple monoexponential decay function can well describe the diffusion-induced signal attenuation S:
where D is the diffusion coefficient, S 0 is the signal in the absence of diffusion, and b is known as the b-value, which determines the degree of diffusion weighting in the signal. Although Eq. [1] is extensively referenced in the literature, it is rarely valid in biological tissues because heterogeneous cellular and subcellular microstructures can substantially perturb the Gaussian distribution of diffusion displacement, leading to non-Gaussian diffusion. This non-Gaussianity provides us with a valuable window through which tissue cellularity, vascularity, microstructures, and heterogeneity can be visualized.
b-Value "Spectrum"
The b-value in Eq. [1] , a critical parameter in DWI, not only controls the degree of diffusion-weighting in the image, but also encodes different tissue properties into the DWI signals. Irrespective of the degree of deviation from Gaussian diffusion, MR signals always decrease as b-value increases (Fig. 1 ). The rate of signal decrease, however, depends on the b-values. At a relatively low b-value (eg, b <200 s/mm 2 ), the signal decays rapidly because fast water movement in capillary vessels can cause substantial signal loss in addition to diffusion-induced signal attenuation. This effect makes the low b-value region particularly sensitive to tissue vascularity, as further described below in the IVIM model. As b-value increases, signal loss from the capillary vasculature is more complete, making the diffusion process a dominant contributor to the signal attenuation. In this intermediate b-value range (eg, 500-1500 s/mm 2 ), the signal attenuation is sensitive to the spatial scale of a cellular size, and hence strongly correlates with cellularity, as illustrated in Fig. 1 . When the b-value increases further, the signal attenuation enters the "high b-value" regime, where the sensitivity to smaller spatial scale increases, making diffusion MRI suitable for probing tissue microstructural complexity and heterogeneity. A consensus for a high b-value threshold has not been established in the literature. Typically, high b-value refers to b >2000 s/mm 2 for neuro applications and >1000 s/mm 2 for body applications. The varying signal attenuation behavior as a function of b-value is analogous to a spectrum where information content depends on frequency. Hence, the schematic diagram shown in Fig. 1 can be referred to as a "b-value spectrum" to facilitate discussion within the scope of this review.
Monoexponential Model and Cellularity
The monoexponential diffusion model is the original model that remains the most prevalent for cancer imaging applications. Given the relatively low spatial resolution in DWI (eg, 2-5 mm in a linear dimension of a voxel), the intravoxel structural variability and heterogeneity can be substantial. Despite this structural complexity, the monoexponential model uses a single diffusion coefficient, ADC, to approximate the average diffusion process within a voxel. The mathematical expression can be derived by replacing D in Eq. [1] with ADC that can be measured by acquiring two images with different b-values. 4 It was observed that DWI signal in biological tissues decays biexponentially, as shown in Eq. [2a], 15 particularly at high b-values (eg, >1500 s/mm 2 for brain tissues). One of the explanations is that the faster diffusion coefficient (D f ) is associated with the diffusion process in the extracellular space, whereas the slower one (D s ) in the intracellular space because of increased restrictions caused by subcellular structures (Fig. 2) . The voxel-based ADC, therefore, represents the volume-weighted average of the fast and slow diffusion coefficients shown in Eq.
[2b]:
where V f and V s are the volume fractions of the fast and slow diffusion component, respectively. Equation [2b] is important because it links ADC to the cell volume fraction or cellularity of a voxel, provided that V f and V s correspond to extra-and intracellular volumes, respectively. Although such correspondence has been challenged by several experimental observations that indicate that cell membrane likely plays an important role in diffusion compartmentalization, 16 a large number of studies on many types of cancer have indicated strongly that ADC is negatively correlated with cell density or cellularity (average correlation coefficient r = -0.61).
7,17
These studies have established ADC as a quantitative surrogate for tissue cellularity.
IVIM Model and Vascularity
In addition to the intra-and extracellular spaces, microvasculature can also be a significant component in an image voxel ( Fig. 2) , particularly in cancerous tissues due to angiogenesis. By including the vascular contribution to the signal, the IVIM model extends the monoexponential diffusion model into the following form 9,10 :
where f is the volume fraction of the vasculature in a voxel and D* is a pseudodiffusion coefficient that corresponds to water movement in the microvasculature, or the perfusion process. The first term in Eq. [3] represents the vascular contribution, whereas the second term accounts for the diffusion contribution. To capture both contributions, a minimum of three bvalues are required; for example, b = 0, 50, and 800 s/mm 2 , as typically used for liver imaging. Since water movement in perfusion is much faster than that in diffusion, a relatively small b-value (50-200 s/mm 2 ) is used to sensitize perfusion without causing excessive signal attenuation. The corresponding D* can be obtained by using the two lower b-value images (eg, b = 0 and 50 s/mm 2 ), while ADC can be calculated from the higher b-value images (eg, b = 50 and 800 s/mm 2 ). Either f or D* can be used to approximate tissue perfusion. The combination of these two parameters (fD*) has also been used for improved performance. 11, 18 It should be noted 23 etc. The vast majority of these models have been developed for the brain without a specific focus on cancer imaging. One of these models, VERDICT, however, has been developed for cancer applications and successfully applied to colorectal and prostate cancers. 12 VERDICT divides each voxel into three compartments to capture the main tumorous tissue features that influence the DWI signal. These three compartments include 1) water trapped in cells, 2) water in the vascular network, and 3) interstitial water. The signal in DWI can, therefore, be expressed as the summation of these three compartments: S = P 3 i = 1 f i S i , where f i is the volume fraction of each compartment whose signal intensity is S i . Unlike the monoexponential or IVIM model, VERDICT provides estimates of specific tissue properties such as the size and packing density of the cells, as well as the vascular and extracellular-extravascular volume fractions.
Another compartmentalized model is RSI, initially developed for the brain, 23 but recently extended to the prostate. 24 In RSI, the diffusion signal is modeled as a mixture of up to eight components with varying degrees of diffusion restriction or hindrance. Each component describes the signal dependence on a specific tissue property (eg, cell size, density, orientation, etc.). The overall signal thus becomes the weighted sum of these components. By determining the individual weights using a generalized linear estimation technique, the underlying tissue parameters (eg, size and shape/orientation of hindered and restricted water compartments) can be obtained.
Unlike the compartmentalized models, noncompartmentalized models do not assume a specific number of tissue compartments. Instead, the possible tissue compartmentalization is embedded in model parameters such as diffusion heterogeneity index, distributions of diffusion coefficients, or kurtosis. Examples of noncompartmentalized models include diffusion kurtosis imaging (DKI), 25 [4] , generalizes the monoexponential Gaussian model to the nonGaussian regime. It offers two parameters: diffusion coefficient (similar to ADC) and dimensionless kurtosis K, which describes the deviation of water molecular displacement from a Gaussian distribution.
Mathematically, the kurtosis model incorporates a second-order term to account for deviations from Gaussian diffusion behavior. Its biophysical basis has been discussed in a number of recent studies aimed at establishing a link between K and specific aspects of tissue microstructures. [32] [33] [34] It is worth noting that the DKI model has been more commonly used to study diffusion anisotropy as an extension of diffusion tensor imaging (DTI), which involves image acquisitions with multiple b-values and multiple diffusion gradient directions. For clinical applications in cancer imaging, where the imaging times are an important consideration, DKI can be used by acquiring trace-weighted images to save time and remove the sensitivity to diffusion anisotropy. 3 Another noncompartmentalized model is the stretched exponential model (Eq. [5] ) where diffusion non-Gaussianity is accounted for by introducing an empirical parameter α. In this model, the diffusion coefficient D is referred to as distributed diffusion coefficient (DDC) because a single diffusion coefficient is no longer sufficient to describe diffusion process in a complex and heterogeneous tissue.
The empirical nature of the stretched exponential model was mitigated by the development of the FROC and CTRW models. [27] [28] [29] 35 Both models recognize the presence of intravoxel diffusion heterogeneity in space and time. Water molecules can produce a variable spatial displacement in each move (ie, spatial heterogeneity), or can take a variable temporal interval to make a move (ie, temporal heterogeneity). The spatial heterogeneity is a direct reflection of the underlying tissue structural complexity, while the temporal heterogeneity reflects the likelihood of the water molecule to be "trapped" or "released" while it diffuses through the complex tissue structures. Hence, both spatial and temporal diffusion heterogeneities originate from the underlying tissue structural heterogeneity. In the CTRW model, the temporal and spatial diffusion heterogeneities are described by two model parameters, α and β, respectively:
where E α is a Mittag-Leffler function 28, 29 of the α order, β corresponds to spatial diffusion heterogeneity, and both α and β are bounded in the range of 0 and 1. In a homogeneous medium, both α and β are equal to 1 and Eq. [6] reduces to the monoexponential decay function in Eq. [1] . 29 As the degree of tissue heterogeneity increases, these parameters become progressively less than 1.
The FROC model is a simplification of the CTRW model by considering the spatial heterogeneity only (ie, assigning α = 1). For a Stejskal-Tanner diffusion gradient G d with a duration δ and gradient separation Δ, the diffusioninduced signal loss is expressed as 27 :
where μ is a spatial constant to preserve the nominal units of diffusion coefficient D in mm 2 /s. Both CTRW and FROC models have been increasingly used for cancer imaging, as detailed later. To use either model, a relatively high b-value (eg, ≥3000 s/mm 2 ) is required.
To apply high b-value DWI to studying tissue microstructures, it is important to recognize that the ability of probing tissue microstructures depends heavily on the diffusion time-a parameter that is typically fixed on commercial MRI scanners. The diffusion time controls the spatial scale of the tissue structures under investigation. 36 For a spin echo sequence, the shortest diffusion time is determined by the available gradient strength, while the longest is by the maximal echo time (TE) to retain a minimally required signal-to-noise ratio (SNR). These limits can be overcome by using alternative pulse sequences. 36 In addition to the specific diffusion models outlined above, other diffusion models have also been used for cancer imaging. Table 1 summarizes a set of selected diffusion models, the key model parameters, the typical b-value ranges, and the biological significance of these models in relation to cancer-relevant tissue properties.
Clinical Applications
Detection and Diagnosis Despite its relatively low spatial resolution, DWI plays an important role in cancer detection because it can offer advantages in tumor-to-normal tissue contrast. Because water diffusion in a highly cellular tumor is more restricted than in normal tissues, a higher b-value can more effectively suppress signals from the normal tissue, enhancing tumor-to-normal tissue contrast and leading to hyperintense signals in the tumor (Fig. 3) . Such enhanced contrast can considerably improve the conspicuity of small lesions (Fig. 4) , 37 tumors on hollow organs, 38 and tumors otherwise obscured by strong background from normal tissues. 39 While the majority of the reported studies have used low to moderate b-values (eg, 800 s/mm 2 for the liver, and 1000 s/mm 2 for the brain) because of the SNR considerations, the benefits of using a higher b-value beyond the conventional have been increasingly demonstrated in recent studies. Ichikawa et al employed a b-value of 1000 s/mm 2 to detect colorectal adenocarcinoma in a cohort of 33 patients with colonoscopically proven colorectal cancers. 40 They achieved a high sensitivity of 90% and a specificity of 100%. Over the years, the threshold for high b-value is evolving. Kim et al 41 , illustrating the benefits of high b-values for detecting prostate cancer. 42 The potential value of high b-values for cancer detection has also been investigated in several other cancers. 43, 44 Despite some conflicting reports, the general consensus is that higher b-values can provide better conspicuity for tumor detection, provided that an adequate SNR (eg, 5-10) can be maintained. 45, 46 This has led to recent adoption of high b-value (1400-2000 s/mm 2 ) DWI in Prostate Imaging Reporting and Data System (PI-RADS) Version 2. 47 Achieving an adequate SNR at high b-values can be challenging. A possible solution is to synthesize high b-value images from acquired low b-value images (which have high SNR) using a specific diffusion model-commonly a monoexponential model. As such, the synthetic or computed images cannot be used with advanced diffusion models other than the model from which they are synthesized. The use of quantitative information from DWI can further aid in differential diagnosis of tumors. Because the effect of non-Gaussian diffusion increases with the b-value, it is widely reported that the ADC value depends on b-value selections, particularly in the high b-value range (eg, b >1000 s/mm 2 ). 48 With the ability to offer multiple parameters, nonGaussian diffusion models can be helpful in cancer characterization and/or detection. For example, diffusion parameter This is a q-space imaging technique that requires varying both diffusion gradient and diffusion time.
maps can be used individually or conjointly to create or enhance the tumor-to-tissue contrast. parameters between prostate cancer, benign prostatic hyperplasia (BPH), and benign peripheral zone (PZ) lesions. 32 In particular, K is significantly higher in prostate cancer than in nonstromal BPH and healthy PZ. Other non-Gaussian models, such as stretched exponential, 49, 50 VERDICT, 12 and RSI, 24 have also been successfully used for prostate cancer detection. Although the majority of the studies have demonstrated the advantages of non-Gaussian models with high b-values, one study has shown that the DDC ratio between the breast cancer and glandular tissue, estimated from a stretched exponential model, was not statistically different than the ADC ratio. 51 In addition, another study did not find that the FROC model parameters outperformed ADC for differentiating between malignant and benign breast lesions, likely because of the intrinsic high degrees of heterogeneity within the breast tissue and/or a moderate maximal b-value employed in the study. 13 At the other end of the b-value spectrum, the IVIM model has been increasingly applied to cancer diagnosis and detection, as reviewed by Koh et al. 11 Improved performance of IVIM parameters (D*, D, and f ) over ADC has been reported for diagnosing focal liver lesions, 52 and differentiating between benign and malignant breast lesions. 53 The FIGURE 3: Examples of using DWI for tumor detection. Images in each row were acquired from the same patient. a,b: On a patient with gastric cancer in antrum (arrow), the contrast between the lesion (arrow) and the background tissue was much higher on the DWI with b = 1000 s/mm 2 (b) than on the T 2 W image (a). c,d: T 1 enhancement was observed on a patient with esophagogastric junction cancer (arrow (c)). However, the opposite larger curvature wall also displayed strong enhancement (double arrow), making it difficult to determine the tumor border. On the DWI with b = 1000 s/mm 2 (d), the normal wall signal was effectively suppressed, making the cancer easily detectable (arrow). e-h: On a patient with gastric cancer in antrum, the conspicuity of the tumor improved substantially when the b-value was increased from 300 s/mm 2 in (e) to 1200 s/mm 2 in (f ). Similar improvement was observed on another patient when the b-value was increased from 500 s/mm 2 in (g) to 1200 s/mm 2 in (h). IVIM model has also been shown useful in discriminating lung cancer from obstructive pulmonary consolidation. 39 Very recently, Qi et al showed that the combination of two IVIM parameters, f and D, can improve differentiation of malignant versus benign mediastinal lymph nodes, 19 which is of great value for determining lymph node involvement in lung cancer and other neoplasms. In addition to detecting primary tumors, DWI with high b-values has also been used to facilitate the detection and diagnosis of residual or recurrent tumors after surgical or nonsurgical local treatments (stereotactic body radiation therapy or SBRT, transcatheter arterial chemoembolization, radiofrequency ablation or RFA, stereotactic radiotherapy/ radiosurgery or SRT/SRS, etc.) or palliative therapy.
54,55 Figure 6 shows images from a hepatocellular carcinoma (HCC) patient who received RFA. No obvious enhancement was seen near the post-RFA area in the T 1 -weighted image (Fig. 6a) . However, recurrent lesions were detected as dot-like high signals in DWI (Fig. 6c) . These lesions progressed rapidly after another month (Fig. 6b,d) .
Classification, Grading, and Staging Recent initiatives in predictive, personalized, preemptive, and participatory medicine are shifting the roles of radiology from conventional diagnosis to disease classification, grading, staging, and prognostic assessments. 56 Oncologists are increasingly expecting radiologists to provide pretherapy information, such as tumor classification and grading, to guide their treatment plans in order to achieve an optimal outcome for cancer patients. Unfortunately, conventional MRI based on morphological features is inadequate to meet this challenge. With its sensitivity to tissue microstructures at a subvoxel level, high b-value DWI can contribute immensely to addressing this unmet need. Intratumoral heterogeneity is an important consideration in glioma grading, 57 breast cancer staging, 58 Gleason scoring for prostate cancer, 59 and predicting biological aggressiveness of premalignant esophageal lesions. 60 Previous imaging studies on intratumoral heterogeneity were limited by the achievable voxel size. The advent of high b-value DWI has shown great potential in breaking this barrier and peeking into the voxels. Using a stretched exponential model with a maximal b-value of 4000 s/mm 2 , Kwee et al observed a substantially lower α value in high-grade gliomas than in the normal brain tissues and attributed this difference to elevated intravoxel heterogeneity in the tumor. 61 The intravoxel heterogeneity was more rigorously investigated by relating tissue structural heterogeneity to spatiotemporal diffusion heterogeneities in the FROC and CTRW models. [27] [28] [29] 62 Using an FROC model with a maximal b-value of 4000 s/mm 2 , Sui et al observed a significant difference in β (ie, intravoxel diffusion spatial heterogeneity) not only between pediatric brain tumors and normal brain tissues, but also between low-grade and high-grade tumors. 62 The combination of β and D from the FROC model produced a diagnostic accuracy of 92.5% for differentiating low-and high-grade pediatric brain tumors, considerably outperforming that of ADC (accuracy = 80.6%). Similar results were also obtained for differentiating low-and high-grade gliomas in adults using an FROC model 63 ( Fig. 7) , and for differentiating low-and high-grade brain tumors in children using a CTRW model where both spatial and temporal diffusion heterogeneities are considered. 29 Diffusion-based tumor heterogeneity studies are not limited to the brain tumors and has been extended to breast cancer, 13 prostate cancer, 64 GIST, 14 and others. In addition, diffusionbased tumor heterogeneity studies are not limited to the aforementioned models. For example, by investigating diffusional variance caused by microscopic anisotropy and isotropic heterogeneity, Szczepankiewicz et al demonstrated that a high b-value DWI technique, known as density by diffusional variance decomposition (DIVIDE), was also sensitive to brain tumor heterogeneity. 65 Other aspects of tissue microstructures can also be probed through non-Gaussian diffusion parameters for tumor characterization. Zhu et al found kurtosis derived from DKI demonstrated a stronger correlation with histologic grades and T staging of rectal cancer compared with ADC. 33 Wen et al applied NODDI to characterize gliomas at 7T. 66 Significant differences in NODDI parameters were observed between the tumor and the normal-appearing white matter. However, no significant differences were found across different glioma grades. 66 Bai et al 34 compared the performance for glioma grading using monoexponential, biexponential, stretched exponential, and DKI models with a b-value up to 5000 s/mm 2 . Their results indicate that α in the stretched exponential model and mean K in the DKI model outperformed the conventional diffusion parameters such as ADC for glioma grading. The optimal parameters for tumor grading depend strongly on specific tumors. In another study on differentiating types I and II epithelial ovarian cancer (EOC) using high b-value DWI with monoexponential, biexponential, and stretched exponential diffusion models, 67 ADC, D from the IVIM model, and DDC were all found adequate for EOC differentiation, but there was no significant difference among these parameters. Yet another study by Roethke et al reported no significant benefit of DKI for detecting and grading of prostate cancer as compared with ADC in the peripheral zone. 68 In all the studies outlined above, a common challenge is that physical or mathematical parameters from various diffusion models are attempted to improve tumor grading, staging, and characterization. The direct relationship between these parameters to intravoxel tissue microstructures has not been fully established or validated. In addition, the diagnostic accuracy in some high b-value DWI studies may not be as high as those of conventional MRI. However, DWI can be combined with conventional sequences to improve the overall accuracy, as recently demonstrated by Chatterjee et al in a technique known as hybrid multidimensional MRI. 69 Assessing the biological aggressiveness of tumors is another important aspect for cancer patient evaluation and management. With its correlation to cellularity, ADC can be an important marker for biological aggressiveness of tumors, as in the assessment of the NIH risk stratification of GIST. 70 It is generally believed that the lower the ADC, the higher degree of malignancy and the poorer prognosis. Exceptions, however, do exist. Lee et al reported that ADC of the massforming intrahepatic cholangiocarcinoma with poor prognosis was higher, 71 because of abundant fibrous stroma with scanty tumor cellularity. A similar exception can be found in mucinous cancer of the gastrointestinal (GI) tract, which has poorer prognosis but higher ADC because of a large amount of the mucinous lake. 72 Exceptions can also be found in some primary brain tumors that have higher ADC than the surrounding tissue, likely due to the vasogenic edema associated with FIGURE 7: FROC maps of a grade II glioma patient (upper row) and a grade IV glioblastoma patient (lower row). D, β, and μ are the FROC parameters defined in Eq. [7] with their physical meanings explained in the text. In particular, β has been related to intra-voxel tissue heterogeneity. Differences between the two tumors can be seen in each of the three maps.
the tumor, which results in a relatively less net increase (or even decrease) in cellularity within a highly cellular brain tissue.
Evaluation and Prediction of Treatment Response
In recent years, a number of novel cancer treatment regimens have emerged. Neoadjuvant chemotherapy (NACT) has become the standard procedure for many advanced malignant tumors before surgery. Targeted therapy and PD-1/PDL-1 immunotherapy are emerging as an effective alternate to traditional chemotherapy, and have become even the first-line treatment in some situations. 73, 74 Precise radiotherapy, as well as other nonsurgical local treatments (SBRT, TACE, IRA, SRS/SRT, etc.), has prompted cancer treatment into an era of minimal invasiveness. As the treatment options expand, early evaluation, or even prediction, of treatment efficacy becomes increasingly crucial. Traditional response evaluation based on size or morphologic changes, as stipulated in the RECIST criteria, can no longer meet the need for personalized patient care. 75 This represents an excellent opportunity for DWI to become an additional surrogate to complement RECIST or other criteria such as RANO. 76 Together, they have great potential to address the unmet need for treatment assessment and overcome the limitations of the existing criteria.
DWI FOR PREDICTION OF TREATMENT RESPONSE AND
PROGNOSIS. As for prediction, it is generally believed that the lower the pretreatment ADC, the better the treatment responses. [77] [78] [79] [80] A lower pretreatment ADC typically indicates more active tumor parenchyma, which supports a larger amount of blood supply (as opposed to necrotic tissues, for example) to facilitate easier transportation of anticancer agents to the targeted tumors 77 . Conversely, tumors with higher pretreatment ADC can be hypoxic, with a slower metabolism, making them insensitive to radiotherapies. 81 For other treatment methods, however, the situation can be reversed. For example, Mannelli et al found that HCCs with poor response to TACE had significantly lower pretreatment ADC compared to HCCs with good response. 82 Very recently, the IVIM model has also been applied to predicting response to neoadjuvant treatment of breast cancer. 83 It was reported that D* showed prognostic predictability, whereas baseline ADC and D were not significant predictors of response.
DWI FOR ASSESSMENT OF EARLY RESPONSE.
A major unmet need is whether treatment evaluation can be obtained earlier than what RECIST criteria can presently offer, ie, 2-3 months after the initiation of treatment. Some tumors may change rapidly in cellularity, vascularity, microstructures, and heterogeneity in response to targeted agents, but these changes may not result in tumor size change that can be detected morphologically by computed tomography (CT) or MRI.
The sensitivity to cellularity, vascularity, microstructures, and heterogeneity makes DWI an ideal candidate to capture these changes early. DWI for early treatment evaluation was initially illustrated in brain tumors using ADC. 4, 84, 85 Moffat et al showed that substantial ADC change can be observed at 3 weeks during a 6-week course of radiation therapy. 84 This success was extended to a large number of studies where ADC was used for early evaluation of chemotherapy, targeted therapy, and immunothepary. 4, 77 In many of these studies, an ADC change was observed as early as 1-2 weeks after the initiation of treatment. 77 , 86 Tang et al reported a marked ADC increase (44.8%) at 1 week after therapy that was associated with good response to imatinib mesylate in patients with GIST. 87 The strong correlation implies that tumors with low pretreatment diffusion values will respond better to radiotherapy than those with high diffusion values. Over the past few years, an increasing number of non-Gaussian models have been applied to cancer treatment evaluation. McDonald et al recently demonstrated that RSI with high b-values can be more immune to confounding factors such as edema and offers an advantage over ADC in evaluating response of high-grade gliomas to bevacizumab. 88 This is an interesting example of how higher-order DWI modeling can be useful when the primary effect of bevacizumab therapy is on edema and not tumor cellularity. Using an FROC model with a combination of the pretreatment β value and posttreatment change of ADC at 2 weeks, Tang et al demonstrated that GIST response to sunitinib second-line targeted therapy can be assessed at early as 2 weeks after the initiation of therapy. 14 Figure 9 shows an example illustrating the sensitivity of β from the FROC model to sunitinib targeted therapy. Parameters from Gaussian and nonGaussian diffusion models can also be combined across a broad b-value range to improve the performance of response to chemotherapy, as recently demonstrated by Zhu et al, for locally advanced rectal cancer.
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DWI is also useful for evaluating response to nonsurgical local treatment, such as irreversible electroporation (IRE) of pancreatic carcinoma 90 and SBRT of lung cancer. 91 Kokabi et al reported that ADC change 3 hours after TACE treatment could predict the response of unresectable HCC to doxorubicin drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE). 92 Attention should be paid to other pathologic changes, such as gelatinous necrosis and small abscess in tumor after treatment (especially after antiangiogenic targeted therapy for brain tumor 93 ) that may display high signal on DWI, mimicking recurrence (Fig. 10) . Thus, DWI must be used in combination with conventional images to avoid misinterpretation.
DWI AS A SUPPLEMENT TO RECIST CRITERIA AT
REGULAR EVALUATION TIMEPOINTS. Besides prediction and early evaluation, DWI can be also helpful at conventional evaluation timepoints, ie, 2-3 months after therapy, to complement the widely used RECIST criteria. The existing RECIST criteria have at least two limitations. First, RECIST is not suitable for evaluating GI tract tumors because the variable shape of the GI wall precludes reliable measurement of the long lesion dimension. As such, RECIST defines the primary lesions of the GI tract as nontargeted lesions, resulting in a dilemma for NACT evaluation. ADC and its nonGaussian counterparts can provide quantitative indicators to help resolve this dilemma, as demonstrated in a rectal cancer study to evaluate response to chemoradiation therapy 94 and a gastric cancer study to evaluate chemotherapy. 95 In addition, DWI also serves as a sensitive indicator for complete response of rectal cancer or to help clinical evaluation for patients under "wait-and-see" surveillance. 96 Second, new treatment agents such as targeted therapy and immunotherapy may cause the tumor size to increase, but with tissue degenerations (eg, cystic degeneration, necrosis, hemorrhage, and mucinous degeneration). Some of these tissue changes can be measured by DWI, as reported in the GIST response to imatinib and sunitinib treatments, 14, 77 HCC to sorafenib treatment, 97 and lung cancer to antivascular targeted therapy. For tissues in organs with a slower average diffusion coefficient, a higher b-value should be selected, and vice versa. Third, the SNR and diffusion contrast should be simultaneously considered. Although a higher b-value produces a better diffusion contrast, the SNR can be substantially reduced due to the increased diffusion-induced signal loss as well as T 2 -induced signal attenuation caused by a longer TE to support the higher b-value. The optimal balance between the SNR and the image contrast is typically determined empirically. Lastly, a high b-value requires a strong diffusion gradient to be activated for a long time, which may exacerbate artifacts related to gradient-induced vibration and/or eddy currents. 101 A study on pediatric patients reported that parameters based on IVIM or DKI models had worse CV than those from the stretched exponential model. 102 Reproducibility on other high b-values model parameters has not been adequately reported in the literature. When advanced diffusion models are used, a higher b-value and/or larger number of diffusion gradient directions increases the vulnerability to noise and/or motion, which can compromise repeatability and reliability. A comprehensive understanding of repeatability and reliability is needed to accomplish full clinical translation of advanced DWI techniques.
Motion Management During DWI DWI is particularly sensitive to motion during image acquisition. The use of echo planner imaging (EPI) and other motion resilient pulse sequences such as PROPELLER can effectively avoid or manage the intershot motion within the acquisition of an image. However, interimage motion (eg, for different b-values) must also be addressed, particularly for body imaging. Several methods have been used to control motion for body DWI, such as breath-hold to freeze respiratory motion, respiratory triggering to synchronize with breathing, hypotonic agents to control peristalsis, and echocardiography triggering to eliminate the influence of heartbeat. Selection of a proper motion management strategy is highly application-dependent. Chen et al compared four motion management techniques: multiple breath-hold (MBH), free-breathing (FB), respiratory-triggered (RT), and navigator-triggered (NT) diffusion imaging on the liver, and recommended FB because of its superior reproducibility and shorter acquisition times. 103 Studies reported by Bernardin et al 104 and Weller et al 105 are also in favor of FB for DWI of the lung because it provides good intra-and interobserver repeatability in ADC measurements for malignant lung tumors. A general consensus, however, has not been reached. For example, for DWI of the liver, Kim et al recommended BH, 106 whereas Lee et al showed advantages of using echocardiography triggering which was more effective for decreasing regional variability of ADC and IVIM parameters than FB or RT and improved measurement repeatability by reducing cardiac motioninduced errors. 107 In the literature, there appears to be a stronger preference for FB when using a single-shot EPI-based diffusion sequence. With this approach, it is important to ensure image coregistration of tumors across multiple b-values or gradient directions. Otherwise, use of image coregistration software prior to DWI analysis is highly recommended to compensate for both rigid-body and nonrigid-body motions, especially for the liver and GI tract.
Influence of Contrast Agents on DWI Quantitative Measurements Although DWI acquisitions are typically performed before administration of contrast agent, studies have shown that quantification of diffusion parameters does not exhibit a significant difference before and after contrast agent administration (eg, Gd-EOB-DTPA). 108, 109 This gives flexibility in adjusting the order of the pulse sequences in a protocol involving DWI. For example, DWI can be performed during the enhancement delay after contrast injection to take advantage of the "dead time" and thus save the scan times.
ROI Selection for Quantitative Assessment
Selection of ROIs typically involves two steps. The first step is to determine the tumor-containing slice or slices, comprising single-slice (SS) selection, selection of three predefined slices (PD), observer-based (OB) volume, 110 or whole tumor volume (WTV). 111 The WTV method has the best repeatability and interobserver consistency, while the selective OB and SS methods can well approximate the WTV measurement and require significantly less measurement times, facilitating their adoption in a clinical setting.
110,111
The second step involves determination of ROI contours encasing tumor areas within the chosen slice(s). The contour selection should reflect the specific study purpose. If the study is to investigate the biological aggressiveness, for example, the most restricted diffusion area should be selected by including a relatively small ROI in the highest DWI signal area. If the study is to investigate treatment response, the features of the whole tumor should be analyzed, and a contoured single-slice or WTV is recommended. 96, 112 However, when encountering the situation of "node-in-mass" recurrent lesions, a small ROI can be more sensitive than using WTV in evaluating progressive disease (Fig. 11) . Furthermore, some portions of lesion (eg, gelatinous necrosis or small abscess) should be excluded from the analysis, as these areas can exhibit low ADC values, mimicking highly cellular portions of tumor.
Geometric Distortion
The majority of DWI studies are performed using single-shot EPI pulse sequences. As such, geometric distortion associated with EPI must be carefully considered. In diffusion-weighted EPI, image distortion arises from two primary sources: magnetic susceptibility and eddy currents. The magnetic susceptibility can be particularly problematic for body imaging because of different tissue types. Distortion induced by magnetic susceptibility can be mitigated by using a high receiver bandwidth, parallel imaging, multishot sequences, 113 etc. Eddy currents in diffusion-weighted EPI are produced primarily by the diffusion gradient. As the b-value increases, the diffusion gradient becomes stronger and/or TE becomes longer, both of which exacerbate image distortion. Pulse sequences resilient to eddy currents, such as twice-refocused spin echo, can be used for high b-value DWI to reduce image distortion. [114] [115] [116] Various commercial softwares are also available to reduce the distortion after image acquisition.
Limitations and Possible Future Directions
Despite active research with growing number of publications on DWI with b-values spanning a wide range (ie, 0-5000 s/mm 2 ), routine clinical use of DWI for cancer imaging is limited largely to qualitative assessment and quantification with ADC. Clinical adoption of many advanced high b-value DWI techniques with more sophisticated diffusion models is relatively slow. The low SNR, poor spatial resolution, and exacerbated image distortion at high b-values are among the technical impediments for clinical adoption. More important, the overlap in some quantitative diffusion parameters between benign and malignant lesions has limited their clinical utilization, despite the statistical differences observed in research studies. Because of these limitations, DWI must be interpreted in combination with conventional MR images and information from other advanced cancer imaging techniques. 29, 71 Another factor contributing to the slow clinical adoption is the lack of standardization and consensus, analogous to the Babel Tower effect. 117 Standardized image acquisition protocols, analysis procedures, and thresholds of quantitative parameters for diagnosis or treatment evaluation are indispensable for clinical applications. They will help establish guidelines that can be used widely to improve impact. Unfortunately, among the vast amount of publications on DWI for cancer imaging, reports on consensus and standardization are scarce. 4 While each published study provides an excellent "building block," it is difficult to build a tower with blocks of different sizes and shapes.
Recent developments in two exciting areas may bring opportunities to resolve this dilemma and accelerate clinical translation of advanced DWI techniques. The first is radiomics with big data, which can potentially provide novel analysis tools of the existing data and lead to new insights into the best strategy for DWI standardization. This will greatly facilitate clinical trials to provide evidence-based proofs of the high values of advanced DWI for cancer care. The second is the multidisciplinary team (MDT) practice. This clinical practice . A quantitative analysis showed that ADC min was more sensitive than ADC mean during the tumor response and recurrent processes, concurrent with the increase and decrease in ADC, respectively. This illustrates the benefit of using a small ROI to focus on high DWI signal regions in this specific example.
model enhances communication and understanding between radiologists, oncologists, and other clinicians not only during day-to-day patient care but also for conducting clinical trials. The oncologists' strong desire for more robust and sensitive imaging-based cancer biomarkers, coupled with radiologists' advanced quantitative DWI tools, will likely lead to fruitful efforts in standardization. Towards that end, the literature has already shown an encouraging progress on the validation of ADC as a cancer imaging marker in multicenter trials, through implementing standardized protocols across multivendor platforms together with methods for quality assurance during the processes of data collection, archiving, curation, and analysis. 118 
Conclusion
In conclusion, after more than three decades of development, DWI has become an important technique with widespread applications in many areas of cancer imaging, from diagnosis, tumor grading to treatment evaluation and prediction. Although the majority of current cancer applications rely on ADC, the rapid development of high b-value DWI techniques coupled with the resurgence of the IVIM model has shown a strong trend to considerably expand the scope of DWI applications far beyond what ADC offers. At the present stage, reports of these advanced DWI techniques for cancer imaging are predominantly limited to individual findings. With further development in standardization of image acquisition and analysis, additional efforts in well-organized multicenter clinical trials, and enhanced interactions between radiologists and oncologists, DWI across the entire b-value spectrum is well positioned to become a powerful surrogate in cancer imaging to reveal subvoxel tissue cellularity, vascularity, heterogeneity, and microstructures. 
